Zobrazeno 1 - 10
of 48
pro vyhledávání: '"I. P. Kolyadina"'
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 2, Pp 74-82 (2024)
This article provides a review of studies analyzing the etiology, diagnosis, and treatment of Peitz–Jeghers syndrome, as well as the risk of cancer of different locations in patients with this genetic disorder. We report a case of Peitz–Jeghers s
Externí odkaz:
https://doaj.org/article/69f13b810bb4428983d564902c563e51
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 1, Pp 31-38 (2024)
Aim. To assess risk factors for breast cancer in a large population of women with benign breast dysplasia (BBD) followed up for a long time.Materials and methods. This retrospective study included 504 women with BBD followed up for 10 years. Study pa
Externí odkaz:
https://doaj.org/article/fccef588644049108f83ed03a218cc92
Autor:
I. V. Kolyadina
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 1, Pp 89-103 (2024)
This review presents the evolution of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer, describes late relapse phenomenon, provides clinical rationale for escalation of treatment, analyzes the key stages of the metas
Externí odkaz:
https://doaj.org/article/9e0dc10a36ac41af969d515ba1adb06b
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 4, Pp 36-42 (2024)
Background. Long-lasting dyshormonal breast diseases in women represent a risk factor for breast cancer, especially in patients with atypia. Clinical manifestations of fibrocystic breast disease (FBD) and mastopathy, including high-intensity pain cau
Externí odkaz:
https://doaj.org/article/1b64426fa6ab45b9b843b425468dd6df
Autor:
I. V. Kolyadina
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 3, Pp 63-76 (2023)
The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-l
Externí odkaz:
https://doaj.org/article/d580ee40914b4a339c0abfeed76b9863
Autor:
T. M. Zavarykina, P. K. Lomskova, M. A. Kapralova, O. O. Gordeeva, I. P. Ganshina, D. S. Khodyrev, S. V. Khokhlova, I. V. Kolyadina
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 4, Pp 69-80 (2023)
Background. Breast cancer is the most common cancer among women. Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, in which there are no special targets for therapy. Therefore chemotherapy is still leading treatmen
Externí odkaz:
https://doaj.org/article/5ed10ee33c6541e192682c3fd761a34a
Autor:
D. A. Morozov, I. V. Kolyadina, I. V. Poddubnaya, I. P. Ganshina, S. V. Khokhlova, V. V. Kometova, V. V. Rodionov
Publikováno v:
Опухоли женской репродуктивной системы, Vol 17, Iss 4, Pp 38-47 (2022)
Background. The role of neoadjuvant chemotherapy (NACT) in luminal HER2-negative breast cancer (BC) remains highly controversial due to the lack of reliable predictors of drug therapy efficacy.Objective: to evaluate the effectiveness of NACT in patie
Externí odkaz:
https://doaj.org/article/48891bdc57a34ef6aade197e0a894a47
Autor:
I. V. Kolyadina
Publikováno v:
Опухоли женской репродуктивной системы, Vol 17, Iss 3, Pp 59-68 (2021)
The article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to e
Externí odkaz:
https://doaj.org/article/3ea179a9dae8445e87cbc7f2168f9c46
Publikováno v:
Опухоли женской репродуктивной системы, Vol 16, Iss 4, Pp 21-34 (2021)
Objective: to study the radiological and sonographic features of microcarcinomas of various biological subtypes.Materials and methods. The analysis included 59 patients (median age – 55 years) with invasive breast cancer (BC) pT1a–bN0M0 stages at
Externí odkaz:
https://doaj.org/article/b5b47eb0332a446f9ea1322846465256
Autor:
I. V. Kolyadina, I. V. Poddubnaya
Publikováno v:
Опухоли женской репродуктивной системы, Vol 16, Iss 3, Pp 46-56 (2021)
HER2-positive breast cancer is a unique subtype of the disease, not only in terms of aggressive biology, but also in terms of treatment options. Over the past 15 years, the strategy for treating early HER2-positive breast cancer has undergone a real
Externí odkaz:
https://doaj.org/article/5dffac5ff44547f3b26d5cc0c6f2e57b